Status:
ACTIVE_NOT_RECRUITING
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.
Lead Sponsor:
UNICANCER
Collaborating Sponsors:
Institut Curie
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Hereditary Breast and Ovarian Cancer
Mutation
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
TUMOSPEC is a national family study designed to measure the relative and absolute risk of cancer for carriers of deleterious mutations to these "new" breast cancer (BC) susceptibility genes. Index cas...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Index case eligibility:
- Any person with an indication for a BRCA1/BRCA2 gene analysis and who has been offered TUMOSPEC panel screening.
- Age ≥18 years.
- Family member eligibility:
- Family members will be eligible if the mutation identified in the Index Case is considered deleterious.
- Any family member to the first and second decree or a cousin of the Index Case. Family members from both sides of the family will be invited to take part.
- Age ≥18 years.
- Exclusion Criteria:
- People deprived of their civil liberties or who are under judicial protection or guardianship.
- Patients unable to answer the questionnaire for social or psychological reasons.
- Children of the index cases, of any age.
Exclusion
Key Trial Info
Start Date :
September 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
7274 Patients enrolled
Trial Details
Trial ID
NCT03246841
Start Date
September 21 2017
End Date
December 31 2025
Last Update
December 12 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Gustave Roussy
Paris, France
2
Institut Curie - PIGE
Paris, France